Intraocular tumors are primarily diagnosed clinically. However, ancillary tests such as fluorescein angiogram provides excellent visualization of retinal tumors while indocyanine green angiography reveals intrinsic vascular patterns of choroidal tumors. In this review, we contrast angiographic patterns of a variety of retinal, choroidal, and iris tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/APO.0000000000000323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case of cutaneous melanoma metastatic to the ciliary body and choroid with complete regression via systemic dual checkpoint inhibitor therapy.
BMC Ophthalmol
January 2025
Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Background: Cutaneous melanoma is the leading cause of death from cutaneous malignancy and tends to metastasize lymphatically and hematogenously to the lung, liver, brain, and bone; it is a rare source of metastatic disease to the eye. Herein we provide a case report of cutaneous melanoma metastatic to the ciliary body and choroid involving clinical examination, slit lamp photography, and B-scan ultrasonography.
Result: A 55-year-old female with known metastatic cutaneous melanoma presented with pain, a large ciliochoroidal mass, visual decline, and diffuse intraocular inflammation.
A retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience.
Brachytherapy
January 2025
Ocular Oncology and Radiology Department, S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.
Purpose: To retrospectively evaluate the efficacy of plaque brachytherapy for the treatment of retinoblastoma.
Methods: We retrospectively reviewed the clinical records of 163 patients (186 eyes, 333 tumors) treated with brachytherapy (Ru or Sr plaques) for intraocular retinoblastoma between November 2007 and August 2023.
Results: Complete tumor control was achieved in 273 tumors (82%).
Uveal metastasis: clinical characteristics, treatment, and prognostic factors in a cohort of 161 patients in China.
Can J Ophthalmol
January 2025
Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Objective: To investigate the clinical and prognostic features of uveal metastasis in a Chinese population and compare these features across different primary cancers.
Design: Retrospective cross-sectional study.
Participants: 161 patients with uveal metastasis at Beijing Tongren Hospital.
[Health Related Quality of Life in retinoblastoma patients].
Andes Pediatr
August 2024
Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Unlabelled: Retinoblastoma (Rb) is the most common intraocular cancer in children and, along with its treatment, can negatively impact the Quality of Life (QoL). Few studies have explored this subject in these patients; none in Latin America.
Objective: To evaluate the general, physical, emotional, social, and school quality of life of patients treated for Rb and to analyze which patient, disease, or treatment factors are associated with worse outcomes.
Management of choroidal/ciliary body metastasis in the era of targeted cancer therapy.
Front Oncol
December 2024
Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, United States.
Introduction: Choroidal metastases from systemic malignancies are the most common intraocular malignancies in adults. External beam radiation (EBR) has historically been first-line therapy for metastatic tumors to the choroid. However, good responses have been described with newer targeted biologics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!